These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21953353)

  • 1. How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approach.
    Fleischer F; Gaschler-Markefski B; Bluhmki E
    Stat Med; 2011 Dec; 30(29):3373-86. PubMed ID: 21953353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
    Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
    J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
    Amit O; Mannino F; Stone AM; Bushnell W; Denne J; Helterbrand J; Burger HU
    Eur J Cancer; 2011 Aug; 47(12):1772-8. PubMed ID: 21429737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.
    Mannino FV; Amit O; Lahiri S
    J Biopharm Stat; 2013; 23(5):971-85. PubMed ID: 23957510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
    Denne JS; Stone AM; Bailey-Iacona R; Chen TT
    J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model free audit methodology for bias evaluation of tumour progression in oncology.
    Stone A; Macpherson E; Smith A; Jennison C
    Pharm Stat; 2015; 14(6):455-63. PubMed ID: 26435269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
    Zhang JJ; Zhang L; Chen H; Murgo AJ; Dodd LE; Pazdur R; Sridhara R
    Clin Cancer Res; 2013 May; 19(10):2637-45. PubMed ID: 23532893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
    Ishak KJ; Caro JJ; Drayson MT; Dimopoulos M; Weber D; Augustson B; Child JA; Knight R; Iqbal G; Dunn J; Shearer A; Morgan G
    Value Health; 2011; 14(5):672-8. PubMed ID: 21839405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying sensitivity analyses to overall survival in cancer clinical trials.
    Wolff SN
    J Clin Oncol; 2010 Jul; 28(19):e323; author reply e324. PubMed ID: 20516448
    [No Abstract]   [Full Text] [Related]  

  • 14. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity analysis of progression-free survival with dependent withdrawal.
    Ruan PK; Gray RJ
    Stat Med; 2008 Apr; 27(8):1180-98. PubMed ID: 17768718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sympathetic bias.
    Levy DM; Peart SJ
    Stat Methods Med Res; 2008 Jun; 17(3):265-77. PubMed ID: 17925315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On assessing the presence of evaluation-time bias in progression-free survival in randomized trials.
    Kay R; Wu J; Wittes J
    Pharm Stat; 2011; 10(3):213-7. PubMed ID: 20568099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the assessment of progression in randomised cancer treatment trials.
    Dancey JE; Dodd LE; Ford R; Kaplan R; Mooney M; Rubinstein L; Schwartz LH; Shankar L; Therasse P
    Eur J Cancer; 2009 Jan; 45(2):281-9. PubMed ID: 19097775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.